The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice

Nursing

Volumn 26, Issue 4, 1996, Pages

  Yang, Zandong ^a   Chen, Meng ^a   Fialkow, Lawrence B ^a   Ellett, Justin D ^a   Wu, Runpei ^a   Nadler, Jerry L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cytokine; Diabetes; Lisofylline; Macrophage; Streptozotocin

Indexed keywords

DIFFERENTIATION ANTIGEN; DRUG DERIVATIVE; GAMMA INTERFERON; INSULIN; INTERLEUKIN 10; INTERLEUKIN 4; LISOFYLLINE; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DIABETES MELLITUS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; PANCREAS ISLET; RANDOMIZATION; SECRETION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, DIFFERENTIATION; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INSULIN; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; PENTOXIFYLLINE; RANDOM ALLOCATION; STREPTOZOCIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642273986     PISSN: 03604039     EISSN: 15388689     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev. 1994; 15:516-542.
2. Karlsson MGE, Lawesson SS, Ludvigsson LJ. Th1-like dominance in high-risk first-degree relatives of Type I diabetic patients. Diabetologia. 2000; 43:742-749.
3. Rabinovitch A, Suarez-Pinzon W, El-Sheikh A, et al. Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: expression of Th1 cytokines correlates with β-cell destructive insulitis and IDDM. Diabetes. 1996; 45:749-754.
4. Bao M, Yang Y, Jun HS, Yoon JW. Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 2002; 168:5369-5375.
5. Stephens LA, Thomas HE, Ming L, et al. Tumor necrosis factor-α-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic β cells. Endocrinology. 1999; 140:3219-3227.
6. Pukel C, Baquerizo H, Rabinovitch A. Destruction of rat islet cell monolayers by cytokines; synergistic interactions of IFN-γ, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes. 1988; 37:133-136.
7. Chen M, Yang Z, Wu R, Nadler JL. Lisofylline, a novel antiinflammatory agent, protects pancreatic β-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Endocrinology. 2002; 143:2341-2348.
8. Campbell IL, Iscaro A, Harrison LC. IFN-γ and tumor necrosis factor-α. Cytotoxicity to murine islets of Langerhans. J Immunol. 1988; 141:2325-2329.
9. Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today. 1994; 15:115-120.
10. Nicoletti F, Meroni PL, Landolfo S, et al. Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-γ [letter]. Lancet. 1990; 36:319.
11. Cailleau C, Diu-Hercend A, Ruuth E, et al. Treatment with neutralizing antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes. 1997; 46:937-940.
12. Nicoletti F, Zaccone P, Di Marco R, et al. The effects of a nonimmunogenic form of murine soluble interferon-γ receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology. 1996; 137:5567-5575.
13. Rice GC, Rosen J, Weeks R, et al. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock. 1994; 1:254-266.
14. George C, Fantuzzi G, Bursten S, et al. Effects of lisofylline on hyperoxia-induced lung injury. Am J Physol. 1999; 276:L776-L785.
15. Bleich D, Chen S, Bursten SL, Nadler JL. Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1β-induced dysfunction in cultured rat islets. Endocrinology. 1996; 137:4871-4877.
16. Coon ME, Diegel M, Leshinsky N, Klaus SJ. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J Immunol. 1999; 163:6567-6574.
17. Bright JJ, Du C, Coon M, et al. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug Lisofylline. J Immunol. 1998; 161:7015-7022.
18. Furth AM, Eerhard-Seijmonsbergen EM, Furth RV, Langermans JAM. Effect of Lisofylline and Pentoxifylline on the bacterial-stimulated production of TNF-α, IL-1β and IL-10 by human leukocytes. Immunology. 1997; 91:193-196.
19. Brosky G, Logothetopoulos J. Streptozotocin diabetes in the mouse and guinea pig. Diabetes. 1969; 18:606-611.
20. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 1976; 193:415-417.
21. Anastasi E, Dotta F, Tiberti C, et al. Insulin prophylaxis downregulates islet antigen expression and islet autoimmunity in the low-dose STZ mouse model of diabetes. Autoimmunity. 1999; 29:249-256.
22. Cossel L, Schneider E, Kuttler B, et al. Low dose streptozotocin induced diabetes in mice. Metabolic, light microscopical, histochemical, immunofluorescence microscopical, electron microscopical and morphometrical findings. Exp Clin Endocrinol. 1985; 85:7-26.
23. Gotoh M, Maki T, Kiyoizumi T, et al. Brief communications: an improved method for isolation of mouse pancreatic islets. Transplantation. 1985; 40:437-439.
24. +T cells expressing identical endogenous TCRα chains. J Immunol. 1996; 157:4726-4735.
25. Yang Z, Chen M, Wu R, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol. 2002; 168:6479-6485.
26. Flotte TJ, Springer TA, Thorbecke GJ. Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets. Am J Pathol. 1983; 111:112-124.
27. Rossini AA, Like AA, Chick WL, et al. Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci USA. 1977; 74:2485-2489.
28. Yang Z, Chen M, Wu R, et al. The anti-inflammatory compound lisofylline prevents Type 1 diabetes in non-obese diabetic mice. Diabetologia. 2002; 45:1307-1314.
29. +T-cells. Diabetes. 1995; 44:354-359.
30. Campbell IL, Oxbrow L, Koulmanda M, Harrison LC. IFN-γ induces islet cell MHC antigens and enhances autoimmune streptozotocin-induced diabetes in the mouse. J Immunol. 1988; 140:1111-1116.
31. Flodstrom M, Tyrberg B, Eizirik DL, Sandler S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes. 1999; 48:706-713.
32. Herold KC, Montag AG, Fitch FW. Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozotocin. Diabetes. 1987; 36:796-801.
33. Herold KC, Vezys V, Sun Q, et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1996; 156:3521-3527.
34. Lukic ML, Stosic-Grujicic S, Ostojic N, et al. Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem Biophys Res Commun. 1991; 178:913-920.
35. Rabinovitch A. Immunoregulatory and cytokine imbalance in the pathogenesis of IDDM: therapeutic intervention by immunostimulation? Diabetes. 1994; 43:613-621.
36. Pukel C, Baquerizo H, Rabinovitch A. Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferon-γ, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes. 1988; 37:133-136.
37. Sarvetnick N, Shizuru J, Liggitt D, et al. Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ. Nature. 1990; 346:844-847.
38. Jacob CO, Aiso S, Michie SA, et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin 1. Proc Natl Acad Sci USA. 1990; 87:968-972.
39. Rothe H, Kolb H. Strategies of protection from nitric oxide toxicity in islet inflammation. J Mol Med. 1999; 77:40-44.
40. Corbett JA, Sweetland MA, Wang JL, et al. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci USA. 1993; 99:1731-1735.
41. Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996; 382:171-177.
42. +T-cells in T-cell receptor transgenic NOD mice. Diabetes. 1999; 48:34-42.
43. Yoon JW, Jun HS, Santamaria PS. Cellular and molecular mechanisms for the initiation and progression of β-cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity. 1998; 127:109-112.
44. Shinomiya M, Nadano S, Shinomiya H, Onji M. In situ characterization of dendritic cells occurring in the islets of nonobese diabetic mice during the development of insulitis. Pancreas. 2000; 20:290-296.
45. Lee KU, Amano K, Yoon JW. Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes. 1988; 37:989-991.
46. +T lymphocytes. J Clin Invest 2000; 105:459-468.
47. Rice GC, Brown PA, Nelson RJ, et al. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci USA. 1994; 91:3857-3861.
48. Oka Y, Hasegawa N, Nakayama M, et al. Selective downregulation of neutrophils by a phosphatidic acid generation inhibitor in a porcine sepsis model. J Surgical Res. 1999; 81:147-155.
49. Yang Z, Chen M, Fialkow LB, et al. Inhibition of STAT4 activation by Lisofylline is associated with the protection of autoimmune diabetes [abstract]. Diabetes/Metabol Rese and Rev. 2002; 18:31.